EVO Evotec SE

FDA Catalyst Company
13.32
-0.1  -1%
Previous Close 13.42
Open 13.4
52 Week Low 10.6
52 Week High 35.366631
Market Cap $4,714,018,676
Shares 353,905,306
Float 353,905,306
Enterprise Value $4,817,036,691
Volume 24,153
Av. Daily Volume 81,716
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Cowen & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 11/29/2021

Latest News

    • THE MULTI-TARGET RESEARCH AND DEVELOPMENT PARTNERSHIP WILL FOCUS ON SEVERE SKIN DISEASES, INCLUDING IMMUNE-MEDIATED INFLAMMATORY CONDITIONS SUCH AS ATOPIC DERMATITIS AND NON-MELANOMA SKIN CANCER SUCH AS BASAL CELL CARCINOMA
    • THE COLLABORATION LEVERAGES EVOTEC'S DATA-DRIVEN EVOIR&D PLATFORM FOR INTEGRATED DISCOVERY AND DEVELOPMENT OF FIRST-IN-CLASS THERAPIES AND ALMIRALL'S EXPERTISE IN MEDICAL DERMATOLOGY

    HAMBURG, GERMANY and BARCELONA, SPAIN / ACCESSWIRE / May 19, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) and Almirall S.A. (ALM), a global biopharmaceutical company focused on skin health, announced today a multi-target alliance in Medical Dermatology. The companies aim to discover and develop novel therapeutics…

    View Full Article
    • Partnership Leverages Sernova's Proprietary Cell Pouch System™ with Evotec's iPSC-Based Insulin-Producing Beta Cells
    • Partners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent Diabetes
    • Evotec to Make Strategic Equity Investment of CAD $27 M / €20 M in Sernova
    • Sernova / Evotec Joint Conference Call and Webcast at 8:30 am EDT May 17, 2022

    LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSXV:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, and Evotec SE ((FSE: EVT, NASDAQ:EVO), a global pharmaceutical and life science company, and leading developer of iPSC cell technologies for therapeutic applications…

    View Full Article
    • PARTNERSHIP LEVERAGES IPSC-BASED BETA CELLS FROM EVOTEC'S QRBETA INITIATIVE COMBINED WITH SERNOVA'S PROPRIETARY IMPLANTABLE CELL POUCH™ DEVICE
    • THE GOAL IS THE DEVELOPMENT AND COMMERCIALISATION OF AN OFF-THE-SHELF BETA CELL REPLACEMENT THERAPY FOR INSULIN-DEPENDENT DIABETES
    • EVOTEC MAKES STRATEGIC € 20 M EQUITY INVESTMENT IN SERNOVA
    • EVOTEC/SERNOVA JOINT CONFERENCE CALL AND WEBCAST AT 8.30 AM EDT MAY 17, 2022

    HAMBURG, GERMANY, and LONDON, ON / ACCESSWIRE / May 17, 2022 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) and Sernova Corp. (TSXV:SVA, OTCQB:SEOVF, FSE: PSH))), a clinical-stage company and leader in regenerative medicine cell therapeutics today announced a partnership in the field of diabetes. Both Companies…

    View Full Article
  1. HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480, NASDAQ:EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (BMY) in targeted protein degradation, originally signed in 2018.

    Aim of the eight-year extension is to develop a broad pipeline of molecular glue degraders which are small, drug-like compounds. Bristol Myers Squibb is a leader in this field in particular based on its unique library CELMoD®.

    Under the terms of the agreement, Evotec's proprietary EVO panOmics and EVO panHunter platforms as well as AI/ML-based drug discovery and development platforms will be leveraged.

    Evotec receives an upfront payment…

    View Full Article
    • 8-YEAR EXTENSION AND EXPANSION OF COLLABORATION TO DEVELOP PIPELINE OF MOLECULAR GLUE DEGRADERS
    • COLLABORATION LEVERAGES EVOTEC'S PROPRIETARY EVO PANOMICS AND EVO PANHUNTER PLATFORMS COVERING HIGH-PERFORMANCE MULTI-OMICS AND INTEGRATED AI/ML-SUPPORTED DATA ANALYTICS
    • $ 200 M UPFRONT AS WELL AS NEAR-TERM PERFORMANCE-BASED PAYMENTS
    • DEAL POTENTIAL OF $ 5 BN

    HAMBURG, GERMANY / ACCESSWIRE / May 10, 2022 / Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular…

    View Full Article
View All Evotec SE News